Edge Therapeutics, Inc. (NASDAQ:EDGE) insider Brian A. Leuthner sold 7,500 shares of the stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $10.21, for a total transaction of $76,575.00. Following the sale, the insider now owns 117,736 shares in the company, valued at approximately $1,202,084.56. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Edge Therapeutics, Inc. (NASDAQ:EDGE) traded up 5.52% during mid-day trading on Wednesday, hitting $10.51. 70,286 shares of the company traded hands. The firm has a 50 day moving average of $10.58 and a 200 day moving average of $9.88. The firm’s market capitalization is $324.24 million. Edge Therapeutics, Inc. has a one year low of $7.30 and a one year high of $13.50.

Edge Therapeutics (NASDAQ:EDGE) last posted its earnings results on Tuesday, August 1st. The biotechnology company reported ($0.44) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.44). Equities research analysts expect that Edge Therapeutics, Inc. will post ($1.87) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Edge Therapeutics, Inc. (EDGE) Insider Sells $76,575.00 in Stock” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/06/edge-therapeutics-inc-edge-insider-sells-76575-00-in-stock.html.

A number of institutional investors have recently bought and sold shares of the stock. Trexquant Investment LP purchased a new position in Edge Therapeutics in the 1st quarter worth approximately $143,000. Teachers Advisors LLC grew its stake in Edge Therapeutics by 8.2% in the 4th quarter. Teachers Advisors LLC now owns 28,353 shares of the biotechnology company’s stock worth $354,000 after buying an additional 2,150 shares in the last quarter. Spark Investment Management LLC purchased a new position in Edge Therapeutics in the 1st quarter worth approximately $157,000. TFS Capital LLC purchased a new position in Edge Therapeutics in the 1st quarter worth approximately $209,000. Finally, Wells Fargo & Company MN grew its stake in Edge Therapeutics by 1.7% in the 1st quarter. Wells Fargo & Company MN now owns 11,942 shares of the biotechnology company’s stock worth $109,000 after buying an additional 200 shares in the last quarter. 49.38% of the stock is currently owned by institutional investors and hedge funds.

Several research firms recently issued reports on EDGE. BidaskClub upgraded shares of Edge Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 3rd. Zacks Investment Research lowered shares of Edge Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 3rd.

About Edge Therapeutics

Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.

Insider Buying and Selling by Quarter for Edge Therapeutics (NASDAQ:EDGE)

Receive News & Stock Ratings for Edge Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics Inc. and related stocks with our FREE daily email newsletter.